Literature DB >> 9663893

3-Deoxyglucosone, a promoter of advanced glycation end products in fluids for peritoneal dialysis.

T Linden1, G Forsbäck, R Deppisch, T Henle, A Wieslander.   

Abstract

OBJECTIVE: The accumulation of irreversible formed advanced glycosylation end products (AGE) in the peritoneal cavity might play an important role in the development of ultrafiltration failure and peritoneal membrane destruction. 3-Deoxyglucosone (3-DG), more formally named 3-deoxy-D-erythro-hexos-2-ulose or 3-deoxy-D-erythro-hexosulos is known to be a potent cross-linker responsible for the polymerization of proteins and a precursor of AGE. The purpose of the present study was to determine if the dicarbonyl compound 3-DG, is formed as a glucose degradation product during heat sterilization of fluids for peritoneal dialysis (PD).
DESIGN: Four fluids were examined: a commercially available PD fluid Gambrosol (Gambro, Lund, Sweden); Gambrosol-Bio (Gambro), a new PD-fluid produced under conditions that minimize the generation of toxic glucose degradation products; a fluid prepared in the laboratory by sterile-filtration; and a fluid prepared in the laboratory by heat sterilization.
METHODS: The concentration of 3-DG was analyzed by measuring the concentration of its diaminonaphthalene derivative by HPLC using a Waters Symmetry C18 column.
RESULTS: The 3-DG concentrations in the commercially- and laboratory-prepared heat-sterilized fluids were 118 and 154 micromol/L, respectively. Gambrosol-Bio and the sterile-filtered fluid produced in the laboratory contained 3-DG in concentrations of 12.3 and less than 1.2 micromol/L, respectively.
CONCLUSION: Our results demonstrate that during the heat sterilization of conventional PD-fluids, 3-DG is produced as a degradation product of glucose. It was also demonstrated that, through an alteration of the manufacturing condition, the production of 3-DG could be considerably reduced. We speculate that the presence of 3-DG in unused conventional PD-fluid could act as a local promoter, and increase local AGE formation within the peritoneal cavity.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9663893

Source DB:  PubMed          Journal:  Perit Dial Int        ISSN: 0896-8608            Impact factor:   1.756


  11 in total

Review 1.  Glucose degradation products (GDP's) and peritoneal changes in patients on chronic peritoneal dialysis: will new dialysis solutions prevent these changes?

Authors:  Murali Krishnan; Paul Tam; George Wu; Andrzej Breborowicz; Dimitrios G Oreopoulos
Journal:  Int Urol Nephrol       Date:  2005       Impact factor: 2.370

2.  The promising future of long-term peritoneal dialysis.

Authors:  Dimitrios Oreopoulos; Elias Thodis; Kosmas I Paraskevas
Journal:  Int Urol Nephrol       Date:  2008       Impact factor: 2.370

3.  Morphological characteristics in peritoneum in patients with neutral peritoneal dialysis solution.

Authors:  Chieko Hamada; Kazuho Honda; Kunio Kawanishi; Hirotaka Nakamoto; Yasuhiko Ito; Tsutomu Sakurada; Yudo Tanno; Toru Mizumasa; Masanobu Miyazaki; Misaki Moriishi; Masaaki Nakayama
Journal:  J Artif Organs       Date:  2015-02-14       Impact factor: 1.731

Review 4.  Encapsulating peritoneal sclerosis: the state of affairs.

Authors:  Mario R Korte; Denise E Sampimon; Michiel G H Betjes; Raymond T Krediet
Journal:  Nat Rev Nephrol       Date:  2011-08-02       Impact factor: 28.314

5.  Neuronal damage and shortening of lifespan in C. elegans by peritoneal dialysis fluid: Protection by glyoxalase-1.

Authors:  Andrea Schlotterer; Friederike Pfisterer; Georgi Kukudov; Britta Heckmann; Daniel Henriquez; Christian Morath; Bernhard K Krämer; Hans-Peter Hammes; Vedat Schwenger; Michael Morcos
Journal:  Biomed Rep       Date:  2018-04-03

6.  Factors Generating Glucose Degradation Products In Sterile Glucose Solutions For Infusion: Statistical Relevance Determination Of Their Impacts.

Authors:  J Haybrard; N Simon; C Danel; C Pinçon; C Barthélémy; F J Tessier; B Décaudin; E Boulanger; P Odou
Journal:  Sci Rep       Date:  2017-09-20       Impact factor: 4.379

Review 7.  Role of advanced glycation endproducts and potential therapeutic interventions in dialysis patients.

Authors:  Sandeep K Mallipattu; John C He; Jaime Uribarri
Journal:  Semin Dial       Date:  2012-04-30       Impact factor: 3.455

8.  Infusion fluids contain harmful glucose degradation products.

Authors:  Anna Bryland; Marcus Broman; Martin Erixon; Bengt Klarin; Torbjörn Lindén; Hans Friberg; Anders Wieslander; Per Kjellstrand; Claudio Ronco; Ola Carlsson; Gabriela Godaly
Journal:  Intensive Care Med       Date:  2010-04-16       Impact factor: 17.440

Review 9.  Targeting cannabinoid signaling for peritoneal dialysis-induced oxidative stress and fibrosis.

Authors:  Chih-Yu Yang; Yat-Pang Chau; Ann Chen; Oscar Kuang-Sheng Lee; Der-Cherng Tarng; An-Hang Yang
Journal:  World J Nephrol       Date:  2017-05-06

10.  Identification and quantification of glucose degradation products in heat-sterilized glucose solutions for parenteral use by thin-layer chromatography.

Authors:  Sarah Leitzen; Matthias Vogel; Anette Engels; Thomas Zapf; Martin Brandl
Journal:  PLoS One       Date:  2021-07-02       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.